Non Small Cell Lung Cancer News and Research RSS Feed - Non Small Cell Lung Cancer News and Research

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. [More]
Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers at the University of Virginia School of Medicine have discovered a flaw in the armor of the most aggressive form of lung cancer, a weakness that doctors may be able to exploit to slow or even stop the disease. [More]
Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. [More]
Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. [More]
Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy. [More]
Scientists identify new way to impair tumour growth in lung cancer

Scientists identify new way to impair tumour growth in lung cancer

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore, in collaboration with Harvard Stem Cell Institute, have discovered a new way in which the development of lung cancer can be stopped. [More]
Research could help develop better therapies for new subtype of adenocarcinoma  patients

Research could help develop better therapies for new subtype of adenocarcinoma patients

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. [More]
Cell-free DNA test could help identify liver transplant patients with acute rejection

Cell-free DNA test could help identify liver transplant patients with acute rejection

Today, researchers presented findings at the 68th AACC Annual Scientific Meeting that DNA found circulating in the bloodstream—known as cell-free DNA—can be used to identify liver transplant patients with acute rejection with greater accuracy than conventional liver function tests. [More]
Liquid biopsies hold potential for detecting NSCLC EGFR mutations, predicting cancer recurrence

Liquid biopsies hold potential for detecting NSCLC EGFR mutations, predicting cancer recurrence

Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. [More]
UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors. [More]
Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
First-line nivolumab promising in advanced NSCLC

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer. [More]
ALK fusion variants could influence NSCLC crizotinib response

ALK fusion variants could influence NSCLC crizotinib response

In non-small-cell lung cancer patients with anaplastic lymphoma kinase rearrangement treated with crizotinib, progression-free survival varies according to the ALK fusion variant. [More]
Immunotherapy-treated cancer patients may develop rheumatic disorders

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators. [More]
Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. [More]
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. [More]
Study ignores possibility that drugs, chemicals affect sexes differently

Study ignores possibility that drugs, chemicals affect sexes differently

Many of the medicines we take were only ever tested on men during clinical studies. This poses a distinct danger that females are receiving suboptimal care—and that treatments specifically benefiting women are going undiscovered. [More]
Interdisciplinary approach to improve cancer treatments

Interdisciplinary approach to improve cancer treatments

Whether it focuses on determining why certain cancers develop drug resistance, finding a way to improve individual's immune systems or better understanding cancer cell evolution, fundamental scientific research will "stand up to cancer" with three new awards from the National Science Foundation. [More]
Adjuvant chemotherapy use benefits early-stage NSCLC patients

Adjuvant chemotherapy use benefits early-stage NSCLC patients

The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3 - 7 cm. [More]
Surgery improves survival in late-stage NSCLC patients

Surgery improves survival in late-stage NSCLC patients

Patients with late-stage, non-small cell lung cancer (NSCLC) who have surgery have better survival rates than those who don't, but fewer of these patients are undergoing surgery, UC Davis researchers have found. [More]
Advertisement